Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-161 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Alphageneron
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AP-161 + Keytruda is a combination therapy being developed by Alphageneron for the treatment of metastatic Stage IV non-small cell lung cancer (NSCLC). The regimen combines AP-161, which consists of allogeneic expanded natural killer (NK) cells targeted toward membrane-bound Heat Shock Protein 70 (mHsp70), with Keytruda (pembrolizumab), a programmed death receptor-1 (PD-1) blocking monoclonal antibody. mHsp70 is a tumor-specific antigen overexpressed on the surface of various cancer cells, making it a viable target for NK cell-mediated cytotoxicity. By combining these targeted NK cells with pembrolizumab-mediated checkpoint blockade, the therapy aims to overcome tumor-induced immunosuppression and promote a more robust immune attack against metastatic lesions. The program is currently in Phase 1 clinical trials.
- Other names
- AP-161 + Keytruda
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on AP-161 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-161 + pembrolizumab.